Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Sunshine Biopharma, Inc. SBFM

Healthcare  —  Drug Manufacturers Specialty & Generic
0.84 0.04 5.00% as of 25 Sep
Market cap
$3.3M
P/E
0.0×
Revenue Champion (5y)
Growth Flags show if company had growth for consecutive years
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Sunshine Biopharma, Inc. (SBFM) Business Profile

Updated before January 2025

Company Overview

Sunshine Biopharma, Inc. (SBFM) is a cutting-edge pharmaceutical and biotechnology company dedicated to the research, development, and commercialization of life-saving drugs. Founded in 2006, the company is headquartered in Montreal, Canada, and operates with a mission to address unmet medical needs in oncology, infectious diseases, and other critical therapeutic areas. Sunshine Biopharma is led by a team of seasoned professionals, including its CEO, Dr. Steve Slilaty, who brings decades of experience in molecular biology and drug development. The company’s leadership team is committed to advancing innovative solutions that improve patient outcomes and enhance global healthcare.

Core Business Segments

Sunshine Biopharma operates across several core business segments, focusing on the development of proprietary drugs and the provision of generic pharmaceuticals. These segments include:

1. Proprietary Drug Development

Sunshine Biopharma’s flagship proprietary drug is Adva-27a, a small-molecule anticancer compound that has shown promising results in preclinical studies. Adva-27a is designed to target aggressive cancers, including pancreatic cancer and multidrug-resistant breast cancer. The company is actively pursuing clinical trials to bring this groundbreaking treatment to market.

2. Generic Pharmaceuticals

In addition to its proprietary drug pipeline, Sunshine Biopharma offers a range of generic pharmaceutical products. These include medications for various therapeutic areas such as cardiovascular health, pain management, and infectious diseases. The company’s generic drug portfolio provides affordable and accessible treatment options to patients worldwide.

3. Research and Development Services

Sunshine Biopharma also provides contract research and development (R&D) services to other pharmaceutical companies. These services include drug formulation, preclinical testing, and regulatory support, leveraging the company’s expertise in molecular biology and pharmacology.

Business Model

Sunshine Biopharma’s business model is centered on innovation, collaboration, and diversification. The company generates revenue through the sale of proprietary and generic drugs, as well as through R&D service contracts. By maintaining a balanced portfolio of high-margin proprietary drugs and volume-driven generic products, Sunshine Biopharma ensures financial stability and growth potential. The company also collaborates with academic institutions, research organizations, and industry partners to accelerate drug development and expand its market reach.

Strategic Direction

Sunshine Biopharma is committed to driving growth through innovation and strategic expansion. Key elements of the company’s strategic direction include:

  • Advancing Clinical Trials: Sunshine Biopharma aims to complete clinical trials for Adva-27a and secure regulatory approvals to bring this novel anticancer drug to market.
  • Expanding Generic Drug Portfolio: The company plans to introduce new generic products to meet the growing demand for affordable medications.
  • Sustainability Goals: Sunshine Biopharma is dedicated to minimizing its environmental footprint by adopting sustainable manufacturing practices and reducing waste.
  • Exploring New Therapeutic Areas: The company is actively exploring opportunities in emerging therapeutic areas, such as immunotherapy and personalized medicine, to diversify its product pipeline.

Competitive Landscape

Sunshine Biopharma operates in a highly competitive pharmaceutical and biotechnology industry. Key competitors include:

  • Pfizer Inc.: A global leader in pharmaceuticals and biotechnology, Pfizer competes with Sunshine Biopharma in oncology and infectious diseases.
  • Roche: Known for its innovative cancer treatments, Roche is a major competitor in the oncology space.
  • Teva Pharmaceuticals: As a leading provider of generic drugs, Teva competes with Sunshine Biopharma in the generic pharmaceuticals market.
  • Amgen: A biotechnology giant, Amgen competes in the development of biologics and targeted therapies.

Despite the intense competition, Sunshine Biopharma differentiates itself through its focus on niche markets and its commitment to addressing unmet medical needs.

Risk Factors

Like any pharmaceutical company, Sunshine Biopharma faces several risks, including:

  • Regulatory Challenges: The drug approval process is lengthy and uncertain, posing a risk to the company’s proprietary drug pipeline.
  • Market Dependence: Sunshine Biopharma relies heavily on the success of its flagship product, Adva-27a, which could impact its financial performance if clinical trials are delayed or unsuccessful.
  • Supply Chain Disruptions: The company’s operations could be affected by disruptions in the supply chain for raw materials and active pharmaceutical ingredients (APIs).
  • Competitive Pressure: Intense competition from established players could limit Sunshine Biopharma’s market share and pricing power.

Recent Developments

Sunshine Biopharma has made significant strides in recent years, including:

  • Progress in Adva-27a Development: The company has completed preclinical studies for Adva-27a and is preparing for Phase I clinical trials.
  • Expansion of Generic Drug Portfolio: Sunshine Biopharma has introduced several new generic products, enhancing its market presence.
  • Partnerships and Collaborations: The company has entered into strategic partnerships with academic institutions and research organizations to accelerate drug development.
  • Response to Global Health Challenges: Sunshine Biopharma has actively contributed to addressing global health challenges, including the COVID-19 pandemic, by exploring antiviral drug candidates.

Investment Considerations

Investors considering Sunshine Biopharma should weigh the following factors:

Strengths

  • Innovative Pipeline: The company’s focus on developing novel drugs like Adva-27a positions it for long-term growth.
  • Diversified Revenue Streams: Sunshine Biopharma’s combination of proprietary and generic products provides financial stability.
  • Experienced Leadership: The company’s leadership team has a proven track record in drug development and commercialization.

Risks

  • Regulatory Uncertainty: The success of the company’s proprietary drugs depends on regulatory approvals, which are not guaranteed.
  • Market Competition: Intense competition from established players could impact Sunshine Biopharma’s market share.
  • Financial Constraints: As a smaller company, Sunshine Biopharma may face challenges in securing funding for large-scale clinical trials and commercialization efforts.

Conclusion

Sunshine Biopharma, Inc. is a dynamic pharmaceutical and biotechnology company with a strong focus on innovation and addressing unmet medical needs. While the company faces challenges such as regulatory hurdles and competitive pressure, its diversified business model and promising drug pipeline position it for long-term success. With a commitment to sustainability and strategic growth, Sunshine Biopharma is poised to make a significant impact in the global healthcare industry.